Medtronic is a global medical technology manufacturer producing devices and equipment across cardiovascular care, neuroscience, surgical technologies and diabetes management.
Its extensive portfolio includes pacemakers, defibrillators, heart valves, spinal implants, surgical instruments and robotic-assisted surgery systems.
In March 2026, Medtronic received FDA approval for its OmniaSecure defibrillation lead, the first of its kind approved for conduction system pacing. The company also advanced its Hugo robotic-assisted surgery platform, submitting US regulatory applications to expand its use into general and gynaecological procedures.
Its fiscal 2026 results, reported in June, showed revenue of US$36.4bn, up 8.4%, with continued investment in product innovation and manufacturing capabilities supporting its global medical technology business.